Nature Reviews Cancer

Papers
(The TQCC of Nature Reviews Cancer is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy824
Cancer metabolism: looking forward683
Targeting ferroptosis as a vulnerability in cancer656
Therapeutic cancer vaccines639
RNA in cancer631
Role of RNA modifications in cancer605
Systemic immunity in cancer600
A compendium of mutational cancer driver genes589
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion545
Neutrophil diversity and plasticity in tumour progression and therapy530
Connecting copper and cancer: from transition metal signalling to metalloplasia511
Endoplasmic reticulum stress signals in the tumour and its microenvironment503
The role of ROS in tumour development and progression467
The rediscovery of platinum-based cancer therapy445
The matrix in cancer441
Recent advances and discoveries in the mechanisms and functions of CAR T cells436
The metabolism of cancer cells during metastasis425
p53: 800 million years of evolution and 40 years of discovery412
Metabolism of immune cells in cancer401
Key steps for effective breast cancer prevention372
Long noncoding RNAs in cancer metastasis332
Interleukins in cancer: from biology to therapy321
Advances in bladder cancer biology and therapy308
The cancer–natural killer cell immunity cycle305
The evolving translational potential of small extracellular vesicles in cancer296
The dormant cancer cell life cycle285
Non-genetic mechanisms of therapeutic resistance in cancer285
Linking EMT programmes to normal and neoplastic epithelial stem cells270
Exploiting senescence for the treatment of cancer261
Advancing targeted protein degradation for cancer therapy246
Cancer stem cell–immune cell crosstalk in tumour progression235
Mutations and mechanisms of WNT pathway tumour suppressors in cancer223
The immunological and metabolic landscape in primary and metastatic liver cancer215
Natural killer cells in antitumour adoptive cell immunotherapy213
Cancer progression and the invisible phase of metastatic colonization194
Autophagy in tumour immunity and therapy187
Designing deep learning studies in cancer diagnostics176
The language of chromatin modification in human cancers174
Harnessing multimodal data integration to advance precision oncology170
Targeting DNA damage response pathways in cancer167
Tumour fatty acid metabolism in the context of therapy resistance and obesity166
A new dawn for eosinophils in the tumour microenvironment158
CRISPR in cancer biology and therapy157
Genetic and non-genetic clonal diversity in cancer evolution150
Targeting the DNA damage response in immuno-oncology: developments and opportunities149
Targeting FAK in anticancer combination therapies149
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs144
Antitumour immunity regulated by aberrant ERBB family signalling139
Cancer nanomedicine137
Zebrafish patient avatars in cancer biology and precision cancer therapy134
Sex disparities matter in cancer development and therapy134
MYC protein interactors in gene transcription and cancer134
Targeting CDK4 and CDK6 in cancer130
Programmed death ligand 1 signals in cancer cells130
Mutational signatures: emerging concepts, caveats and clinical applications128
Clonal expansion in non-cancer tissues128
Towards targeting of shared mechanisms of cancer metastasis and therapy resistance123
Overcoming TGFβ-mediated immune evasion in cancer122
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data121
Hyperinsulinaemia in cancer119
Liquid–liquid phase separation drives cellular function and dysfunction in cancer119
The epigenomics of sarcoma119
2-Oxoglutarate-dependent dioxygenases in cancer117
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities113
Prostate carcinogenesis: inflammatory storms112
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer108
Stress and cancer: mechanisms, significance and future directions104
Improving human cancer therapy through the evaluation of pet dogs102
Aneuploidy as a promoter and suppressor of malignant growth99
Mechanisms of immune activation and regulation: lessons from melanoma99
The plasticity of mRNA translation during cancer progression and therapy resistance99
Mitochondrial DNA variation and cancer98
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment96
Tumour predisposition and cancer syndromes as models to study gene–environment interactions91
Advances in germline predisposition to acute leukaemias and myeloid neoplasms91
Polyamines in cancer: integrating organismal metabolism and antitumour immunity90
Artificial intelligence in cancer research, diagnosis and therapy88
A timeline of tumour-associated macrophage biology86
Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis84
Glial and myeloid heterogeneity in the brain tumour microenvironment83
Synthetic biomarkers: a twenty-first century path to early cancer detection82
Cancer proteogenomics: current impact and future prospects82
RNA splicing dysregulation and the hallmarks of cancer78
Decoding leader cells in collective cancer invasion77
Mapping the genomic diaspora of gastric cancer72
Peripheral T cell lymphomas: from the bench to the clinic72
Smokeless tobacco and cigarette smoking: chemical mechanisms and cancer prevention70
Leukaemia: a model metastatic disease69
Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies69
Big data in basic and translational cancer research69
Metabolic rivalry: circadian homeostasis and tumorigenesis64
Emerging themes in cohesin cancer biology63
Targeting the gut microbiota for cancer therapy63
Biology, vulnerabilities and clinical applications of circulating tumour cells60
mRNA-based cancer therapeutics60
Non-coding driver mutations in human cancer57
Targeting transcription cycles in cancer56
Developing dietary interventions as therapy for cancer55
Dynamics and specificities of T cells in cancer immunotherapy53
The coming decade in precision oncology: six riddles52
Therapeutic targeting of tumour myeloid cells50
STAT proteins in cancer: orchestration of metabolism50
Evolving cancer–niche interactions and therapeutic targets during bone metastasis49
Tissue clearing to examine tumour complexity in three dimensions49
Nucleotide metabolism: a pan-cancer metabolic dependency47
Acetyl-CoA metabolism in cancer47
0.029521942138672